June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Analysis of Insurance Status on Diabetic Retinopathy Disease Progression
Author Affiliations & Notes
  • Christina Jayaraj
    Yale School of Medicine, New Haven, Connecticut, United States
  • Akua Frimpong
    University of Vermont Larner College of Medicine, Burlington, Vermont, United States
  • Kristen Harris Nwanyanwu
    Yale School of Medicine, New Haven, Connecticut, United States
  • Footnotes
    Commercial Relationships   Christina Jayaraj None; Akua Frimpong None; Kristen Nwanyanwu Genetech, Code C (Consultant/Contractor)
  • Footnotes
    Support  This publication was made possible by Grant Number 1 K23 EY030530-01 from the National Eye Institute, Yale Diabetes Center Grant P30 DK045735, and the Doris Duke Fund to Retain Clinical Scientists. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH. This work has been supported in part by an unrestricted/challenge award to Yale Eye Center from the Research to Prevent Blindness (RPB), Inc.
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2286. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christina Jayaraj, Akua Frimpong, Kristen Harris Nwanyanwu; Analysis of Insurance Status on Diabetic Retinopathy Disease Progression. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2286.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Diabetic retinopathy (DR) is a leading cause of preventable blindness in the United States. As such, there is a need for evidence-based policy solutions to reduce the burden of disease. To determine the influence of insurance type on DR outcomes, we conducted a retrospective longitudinal cohort study to observe trends in disease progression of Non-Proliferative Diabetic Retinopathy (NPDR) to Proliferative Diabetic Retinopathy (PDR).

Methods : The study includes participants who were seen by an ophthalmologist at the Yale Medical Eye Center or the Dana Eye Clinic from January 1, 2013 to April 1, 2020 with a diagnosis of NDPR during their initial visit. Insurance and age were coded by their status upon initial visit. Insurance type was split into 5 categories: Private, Uninsured, Medicaid, Medicare, and Medicare Managed Care. Private was defined as plans provided through employers, self, community organizations or third-party administrators. Participants <18 years of age or with any diagnosis of PDR prior to or on their initial visit were excluded from the study. Progression to PDR was characterized as at least one PDR diagnosis during the study timeframe. We performed univariate and multivariate regressions to calculate the odds of NPDR to PDR progression. R-programming language was utilized for statistical analysis.

Results : Of the 1,364 participants in the study, 137 progressed from NPDR to PDR in the time frame. When controlling for race/ethnicity, English as a primary language, age, and access to a primary care physician, uninsured participants with NPDR were significantly more likely to progress to PDR when compared to privately insured participants (OR: 2.18 CI:1.09-4.35, p= 0.028). A similar association remained in uninsured participants with NPDR compared to those with Medicare (OR: 3.12 CI: 1.51, p=0.002). On univariate analysis, participants with Medicaid were significantly more likely to progress to PDR when compared to participants with Medicare (OR: 1.91 CI: 1.17-3.11, p=0.010). However, the association no longer remained statistically significant upon multivariate analysis.

Conclusions : Lack of insurance remained significantly associated with increased likelihood of NPDR to PDR progression, even when controlling for other PDR risk factors. Thus, these results indicate that health insurance expansion may be a direct avenue to decreasing preventable blindness in the United States.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×